Sirtris Pharmaceuticals Announces the Appointment of Jeffrey Capello, SVP and CFO of PerkinElmer, to its Board of Directors

  
    
  
  
    
      Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical 
      company focused on discovering and developing small molecule drugs to 
      treat diseases of aging such as Type 2 Diabetes, announced today that 
      Mr. Jeffrey Capello, Senior Vice President and Chief Financial Officer 
      of PerkinElmer, Inc. has been appointed to its Board of Directors.
    
    
      Prior to joining PerkinElmer in 2001, Mr. Capello served as a partner at 
      PricewaterhouseCoopers initially in the United States and later in the 
      Netherlands. Mr. Capello, a licensed CPA, holds a Bachelor of Science 
      degree in Business Administration from the University of Vermont and a 
      Masters of Business Administration degree from Harvard University.
    
    
      “Sirtris is very pleased to welcome Mr. 
      Capello to our Board of Directors. Jeff brings with him extensive 
      experience in the finance and business development areas and will be a 
      tremendous asset to our organization,” said 
      Christoph Westphal, M.D., Ph.D. CEO and Vice Chair of Sirtris 
      Pharmaceuticals, Inc.
    
    
      Mr. Capello commented, “I am very pleased to 
      be joining the Board of such a dynamic and exciting biopharmaceutical 
      company. Sirtris has done an impressive job advancing both the science 
      and clinical development of sirtuin-focused drug candidates to treat 
      diseases of aging, and I look forward to being a part of the company’s 
      efforts moving forward.”
    
    
      This appointment follows the resignations of Alan Crane and John Freund. 
      Christoph Westphal stated, “I would like to 
      take this opportunity to thank Alan and John for their significant 
      contributions to the Sirtris Board and for their support of the company 
      over the past three years.”
    
    
      About Sirtris Pharmaceuticals
    
    
      Sirtris Pharmaceuticals is a biopharmaceutical company focused on 
      discovering and developing proprietary, orally available, small molecule 
      drugs with the potential to treat diseases associated with aging, 
      including metabolic diseases such as Type 2 Diabetes. Our drug 
      candidates are designed to mimic certain beneficial health effects of 
      calorie restriction, without requiring a change in eating habits, by 
      activation of sirtuins, a recently discovered class of enzymes that 
      control the aging process. The company's headquarters are in Cambridge, 
      Massachusetts.
    
    
      This press release contains forward-looking statements within the 
      meaning of the Private Securities Litigation Reform Act of 1995. Such 
      statements include, but are not limited to, the potential therapeutic 
      effects of SIRT1 activators for diseases of aging, such as Type 2 
      Diabetes and disorders, such as MELAS, the progress and results of 
      pre-clinical studies of SIRT1 activators, and the potential of sirtuin 
      modulators to receive regulatory approval. These forward-looking 
      statements about future expectations, plans and prospects of Sirtris 
      Pharmaceuticals involve significant risks, uncertainties and 
      assumptions, including risks related to the lack of results that would 
      provide a basis for predicting whether any of the Company’s 
      product candidates will be safe or effective, or receive regulatory 
      approval, the possibility that results of pre-clinical studies are not 
      necessarily predictive of clinical trial results, the Company's 
      potential inability to initiate and complete pre-clinical studies and 
      clinical trials for its product candidates, the fact that none of the 
      Company's product candidates has received regulatory approvals, the 
      potential inability of the Company to gain market acceptance of the 
      Company's product candidates, and those other risks factors that can be 
      found in the Company's filings with the Securities and Exchange 
      Commission. Actual results may differ materially from those Sirtris 
      Pharmaceuticals contemplated by these forward-looking statements. 
      Sirtris Pharmaceuticals does not undertake to update any of these 
      forward-looking statements to reflect a change in its views or events or 
      circumstances that occur after the date of this release.